Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iowh-032. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684460 | 0.93 | SMPD1 (0.47) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL16727928 | 0.91 | KMT2A (0.52) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL1114340 | 0.91 | SMN1; SMN2 (0.58) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL14684357 | 0.89 | SMPD1 (0.48) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL1114330 | 0.88 | KMT2A (0.51) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL31591596 | 0.88 | KMT2A (0.52) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL18286123 | 0.87 | SMPD1 (0.58) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL1114286 | 0.85 | SMN1; SMN2 (0.52) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL14684367 | 0.85 | SMPD1 (0.46) | SMPD1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL3239876 | 0.85 | PGR (0.48) | SMPD1KMT2APOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115869306-B | Application of IOWH-032 in preparation of medicine for resisting gram-positive bacterial infection | 华中科技大学协和深圳医院 | 2024-03-19 | — | — | CN | claimed |
| CN-114617880-B | Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs | 中国科学院大连化学物理研究所 | 2023-06-06 | — | — | CN | claimed |
| CN-115869306-A | Application of IOWH-032 in preparation of medicines for resisting gram-positive bacterial infection | 华中科技大学协和深圳医院 | 2023-03-31 | — | — | CN | claimed |
| CN-114617880-A | Application of IOWH-032 in preparation of anti-coronavirus medicines and medicines | 中国科学院大连化学物理研究所 | 2022-06-14 | — | — | CN | claimed |
| US-11020379-B2 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | claimed |
| US-10512636-B2 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases | EMORY UNIVERSITY (US) | 2019-12-24 | — | — | US | claimed |
| US-20180147190-A1 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide Compounds for the Management of CFTR Protein Mediated Diseases | UNIV EMORY (US) | 2018-05-31 | — | — | US | claimed |
| EP-3302466-A1 | 3-(PHENYL)-N-(4-PHENOXYBENZYL)-1,2,4-OXADIAZOLE-5-CARBOXAMIDE COMPOUNDS FOR THE MANAGEMENT OF CFTR PROTEIN MEDIATED DISEASES | Emory University (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016196303-A1 | 3-(PHENYL)-N-(4-PHENOXYBENZYL)-1,2,4-OXADIAZOLE-5-CARBOXAMIDE COMPOUNDS FOR THE MANAGEMENT OF CFTR PROTEIN MEDIATED DISEASES | EMORY UNIVERSITY (US) | 2016-12-08 | — | — | WO | claimed |
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | claimed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | claimed |
| EP-2278879-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009131957-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120131644-A | Use of compounds for the treatment of tumors | 上海深度势能科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120131644-A | Use of compounds for the treatment of tumors | 上海深度势能科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147190-A1 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide Compounds for the Management of CFTR Protein Mediated Diseases | CFTR, PKD2, PDE3B | SMPD1 1022/4885KMT2A 3758/4885POLB 3086/4885 |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SMPD1 1643/4885KMT2A 4813/4885POLB 2870/4885 |
| US-11020379-B2 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases | CFTR, PDE3B, PKD2 | SMPD1 1214/4885KMT2A 3977/4885POLB 2979/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | SMPD1 3333/4885KMT2A 2058/4885POLB 3673/4885 |
| US-10512636-B2 | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases | CFTR, PKD2, PDE3B | SMPD1 1022/4885KMT2A 3758/4885POLB 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.